Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Oct;96(42):e6933.
doi: 10.1097/MD.0000000000006933.

Safety of potassium-bearing citrate in patients with renal transplantation: A case report

Lin Wang  1 , Yinglin Cui, Jianwei Zhang, Qinsheng Zhang
Affiliations
Case Reports

Safety of potassium-bearing citrate in patients with renal transplantation: A case report

Lin Wang et al. Medicine (Baltimore). 2017 Oct.

Abstract

Rationale: Urinary lithiasis is one of severe postoperative complications in patients undergoing renal transplantation, possibly leading to anuria, urinary infection, or even acute renal failure. Potassium sodium hydrogen citrate (PSHC), a potassium-bearing citrate, is commonly prescribed to prevent stone formation.

Patient concerns: A 25-year-old man (patient 1) and a 31-year-old man (patient 2) receiving renal transplantation for end-stage renal disease (ESRD) were enrolled in this study. They were given 10 g/day of PSHC granules from the ninth day to the 17th day after surgery. Patient 1 presented chest tightness, nausea, muscle weakness, and ascending paralysis on the 10th day. Patient 2 presented weak waves on EGG on the 17th day. Moreover, their serum potassium concentrations (SPCs) were 7.67 and 6.05 mmol/L, respectively.

Diagnosis: Acute hyperkalemia.

Interventions: Hemo-filtration was performed for patient 1, while patient 2 received 10% calcium gluconate 10 mL, 5% NaHCO3 125 mL, and 10% glucose 500 mL with the addition of 10 units of insulin through intravenous drip.

Outcomes: Their SPCs dropped to the normal range.

Lessons: Physicians should pay close attentions to potential risks caused by PSHC, and monitor the SPCs to minimize the occurrence of hyperkalemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
ECG at presentation for the first patient. ECG at presentation shows dramatically peaked T waves. ECG = electrocardiogram.
Figure 2
Figure 2
The changes in the concentrations of SP (mmol/L), BT (mmol/L), and SCr (×10−2 μmol/L) in the 2 patients along with the passage of time after renal transplantation. (A) It shows that hyperkalemia happens on the 18th day for the first patient 1 day after taking the drug with a SP concentration of 7.67 mmol/L; (B) It shows that hyperkalemia happens on the 14th day for the second patient 5 days after taking the drug with a SP concentration of 6.05 mmol/L. BT = blood tacrolimus, SCr = serum creatinine, SP = serum potassium.
See this image and copyright information in PMC

References

    1. Ferreira Cassini M, Cologna AJ, Ferreira Andrade M, et al. Lithiasis in 1,313 kidney transplants: incidence, diagnosis, and management. Transplant Proc 2012;44:2373–5. - PubMed
    1. Romero-Vargas L, Barba Abad J, Rosell Costa D, et al. Staghorn stones in renal graft. Presentation on two cases report and review the bibliography. Arch Esp Urol 2014;67:650–3. - PubMed
    1. Mamarelis G, Vernadakis S, Moris D, et al. Lithiasis of the renal allograft, a rare urological complication following renal transplantation: a single-center experience of 2,045 renal transplantations. Transplant Proc 2014;46:3203–5. - PubMed
    1. Khositseth S, Gillingham KJ, Cook ME, et al. Urolithiasis after kidney transplantation in pediatric recipients: a single center report. Transplantation 2004;78:1319–23. - PubMed
    1. Cicerello E, Merlo F, Mangano M, et al. Urolithiasis in renal transplantation: diagnosis and management. Arch Ital Urol Androl 2014;86:257–60. - PubMed

Publication types

MeSH terms